Tirzepatide demonstrated significant advantages over dulaglutide in reducing the risk of heart failure and chronic kidney disease progression in patients with type 2 diabetes, according to new real-world data from SURPASS-CVOT presented at the American College of Cardiology Scientific Sessions. The analysis of more than 18,000 patients showed that those treated with tirzepatide had a 21% lower risk of hospitalization for heart failure and a 27% lower risk of kidney disease progression compared to those receiving dulaglutide over a median follow-up of 18 months.
The findings provide important comparative effectiveness data between two widely prescribed incretin-based therapies. Tirzepatide, a dual GIP/GLP-1 receptor agonist, and dulaglutide, a GLP-1 receptor agonist, are both approved for type 2 diabetes management, but this marks one of the first large-scale direct comparisons of their cardiovascular and renal outcomes. The kidney disease composite endpoint included sustained decline in estimated glomerular filtration rate, progression to end-stage kidney disease, or kidney-related death. Both medications have previously demonstrated cardiovascular benefits in their respective trials, but the head-to-head comparison suggests tirzepatide may offer additional protective effects.
The real-world nature of this study is particularly valuable for clinicians making treatment decisions in routine practice. Unlike randomized controlled trials with strict inclusion criteria, this analysis drew from electronic health records representing diverse patient populations across multiple healthcare systems. Researchers adjusted for baseline differences in patient characteristics including age, diabetes duration, kidney function, and cardiovascular risk factors to ensure valid comparisons.
These results could influence treatment algorithms for patients with type 2 diabetes who are at elevated risk for cardiovascular or kidney complications. While both medications remain important therapeutic options, the data suggest tirzepatide may be preferable for patients with existing cardiovascular risk factors or early kidney disease. Further research is needed to confirm these findings in prospective trials and to understand the mechanisms underlying tirzepatide’s potentially superior organ protection compared to GLP-1 receptor agonists alone.
